FILANA THERAPEUTICS, INC.
FLNA · XNASCIK 1069530fmd_1SCEB6XXMG1NZGY16FT8HZGH4J制造业 · 医药制剂模板: 标准
覆盖范围: 2009年1月01日 至 2026年9月30日，共 67 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | – | – | – | – | – | – | – | – | – | – |
| 研发费用 | 9 | 8 | 3 | – | – | 25 | 68 | 89 | 70 | 27 |
| 营业费用合计 | 15 | 12 | 7 | 5 | 6 | 33 | 80 | 106 | 141 | 95 |
| 营业利润 | (15) | (12) | (7) | (5) | (6) | (33) | (80) | (106) | (141) | (95) |
| 利息及投资收益 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | – | – | – |
| 其他营业外收入（支出） | – | – | – | – | – | 0 | 1 | 1 | 0 | (0) |
| 税前利润 | – | – | – | – | – | – | – | – | – | – |
| 所得税费用 | – | – | – | – | – | – | – | – | 0 | 0 |
| 持续经营净利润 | – | – | – | – | – | – | – | – | – | – |
| 净利润 | (15) | (12) | (7) | (5) | (6) | (32) | (76) | (97) | (24) | (91) |
| 归属于普通股股东的净利润 | – | – | – | – | – | – | (76) | (97) | (68) | (91) |